ArticleBMC women's health2026
Association between combined oral contraceptive pills and depression in women with polyendocrine metabolic ovarian syndrome (formerly polycystic ovary syndrome): a comparative cross-sectional study.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe prevalence of depression among women with polyendocrine metabolic ovarian syndrome (PMOS), formerly polycystic ovary syndrome (PCOS), is high. Combined oral contraceptives (COCs) are widely recommended for the treatment of women with PMOS, potentially reducing stress related to managing PMOS symptoms and improving body image. However, concerns exist regarding a potential association between COC use and depression. Given these conflicting effects, the present study aimed to evaluate the relationship of COCs on depression and its associated factors in Thai women with PMOS, compared with non-COC users.
methodsA comparative cross-sectional study was conducted among 96 participants (48 COC users and 48 non-COC users) diagnosed with PMOS using the Rotterdam criteria. Depression was assessed using the Thai version of the Patient Health Questionnaire-9 (PHQ-9). Group comparisons of depression prevalence were analysed using the chi-square test. Predictive factors and interaction analyses were performed using multivariable and Firth's logistic regression, expressed as odds ratios (ORs) and 95% confidence intervals (CIs).
resultsThe prevalence of depression was 37.50% of COC users and 35.42% of non-COC users, with no statistically significant association observed (p-value = 0.832). COC use was not associated with depression. Low testosterone levels were the crucial variables associated with depression among women with PMOS (OR 4.38, 95% CI: 1.45-13.28; p = 0.009), remaining significant after adjustment for age (OR 5.98, 95% CI: 1.83-19.52; p = 0.003). These associations did not affect the interaction of COC use.
conclusionsDepression is highly prevalent among women with PMOS, with prevalence similar between COC users and non-users. Routine screening is recommended for early detection and timely management, regardless of the treatment approach or COC use. Low testosterone levels may be associated with depression in women with PMOS. However, the findings should be interpreted with caution owing to limited statistical power. Larger prospective studies are required to clarify the association between COC use, androgen imbalance, and depression in women with PMOS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.